Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
AMD$508.30+17.47(+3.75%)What Advanced Micro Devices (AMD) Said on Its Q3 Earnings Call9:15:33 PM ETAMZN$248.54+2.83(+1.15%)Filing: Amazon's previously announced layoffs include 95 jobs in Washington state9:11:34 PM ETAMD$508.30+17.47(+3.75%)AMD's OpenAI, Meta chip deals trigger $1 billion quarterly charge9:10:35 PM ETNKE$38.29-0.83(-2.12%)Nike vs. Procter & Gamble: Which Consumer Stock Is a Better Buy for 2027?9:00:01 PM ETNVS$159.26-2.26(-1.40%)Novartis: 3 Key Takeaways for Long-Term Investors8:27:03 PM ETGOOG$276.96-1.04(-0.37%)Should You Buy Alphabet Stock After Anthropic Raised Its Google Commitment to $121 Billion?8:23:01 PM ETAMD$508.30+17.47(+3.75%)AMD EPS: Intel's Drag Makes No Sense8:16:00 PM ETAMD$508.30+17.47(+3.75%)Advanced Micro Devices, Inc. (AMD) Q3 2026 Earnings Call Transcript8:15:53 PM ETAMGN$456.00-4.12(-0.89%)What Amgen (AMGN) Said on Its Q3 Earnings Call8:15:41 PM ETMPLX$57.70-1.22(-2.07%)Dividend Announcements: October 24-30, 2026 (Part 1 Of 2)8:03:58 PM ETAMD$508.30+17.47(+3.75%)GLOBAL MARKETS-US stock futures dip as investors await midterm election results8:03:01 PM ETAAPL$329.82-6.69(-1.98%)Apple Readies Launch of AI-Powered Health App7:42:21 PM ETAMGN$456.00-4.12(-0.89%)Amgen (AMGN) Reports Q3 Earnings: What Key Metrics Have to Say7:30:56 PM ETAAPL$329.82-6.69(-1.98%)Apple: 3 Key Takeaways for Long-Term Investors7:28:50 PM ETAMD$508.30+17.47(+3.75%)Here's why AMD's stock is rising — and sending a confident message about the AI trade7:17:00 PM ETAMD$508.30+17.47(+3.75%)AMD: Expensive For A Reason7:15:26 PM ETGOOG$276.96-1.04(-0.37%)Google responds to political backlash over removing search from schools that ban AI7:10:07 PM ETPLTR$172.60-2.96(-1.66%)Jim Cramer Says the Executioner Is “Axing Palantir and Apple.” What Investors Should Make of It7:09:17 PM ETABBV$285.06-2.88(-1.00%)AbbVie expands Oxford R&D facility as part of £120 million-plus investment7:08:52 PM ETTSLA$391.23-12.63(-3.13%)Tesla misled South Korean customers about automated-driving tech, consumer group alleges7:03:18 PM ETABBV$285.06-2.88(-1.00%)AbbVie expands Oxford R&D facility as part of £120 million-plus investment7:01:03 PM ETAMD$508.30+17.47(+3.75%)Advanced Micro (AMD) Reports Q3 Earnings: What Key Metrics Have to Say7:01:02 PM ETAMD$508.30+17.47(+3.75%)UPDATE 7-AMD forecast eases AI spending fears as data-center sales surge7:00:54 PM ETAMD$508.30+17.47(+3.75%)AMD: The Odds Are Getting Better, But The Bet Still Isn't Worth It (Upgrade)7:00:06 PM ET

CBLL · NASDAQ

CeriBell, Inc.

$23.50 +0.40 (+1.50%)

Company overview

CeriBell, Inc. develops AI-based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company offers the Ceribell System, a novel point-of-care EEG platform designed to address unmet needs of patients in acute care settings. It also provides EEG disposable headbands and pocket-sized battery-operated recorders. CeriBell was formerly known as Brain Stethoscope, Inc., changing its name in August 2015. The company was incorporated in 2014 and is based in Sunnyvale, California.

Sector
Healthcare
Industry
Medical - Devices
Exchange
NASDAQ
Market cap
$902M
Employees
281
Headquarters
Sunnyvale, CA
Website
ceribell.com
CEO
Xingjuan Chao
Listed
October 11, 2024
P/E
-14.42
Dividend yield
0.00%

Company financials

Revenue
$95.1M
Gross profit
$83.4M
Operating income
-$64.9M
EBITDA
-$59.2M
Net income
-$60.4M
EPS
-$1.63
Total assets
$178M
Total debt
$22.1M
Gross margin
87.72%
Net margin
-63.51%
Earnings yield
-6.94%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

15.3218.8422.3725.8929.41
CBLL 1D NASDAQ O27.11H28.89L26.87C28.34+1.38 (+5.12%)Vol575.56K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
CBLLCeriBell, Inc. Stock news CeriBell, Inc. (CBLL) Reports Q3 Loss, Tops Revenue Estimates Zacks Investment Research
CBLLCeriBell, Inc. Stock news CeriBell, Inc. (CBLL) Q3 2026 Earnings Call Transcript Seeking Alpha
CBLLCeriBell, Inc. Stock news Compared to Estimates, CeriBell, Inc. (CBLL) Q3 Earnings: A Look at Key Metrics Zacks Investment Research
CBLLCeriBell, Inc. Stock news CeriBell Q3 Earnings Call Highlights MarketBeat
CBLLCeriBell, Inc. Stock news Ceribell Q3 loss misses estimates; raises 2026 revenue guidance Reuters
CBLLCeriBell, Inc. Press release Ceribell Reports Third Quarter 2026 Financial Results GlobeNewswire
CBLLCeriBell, Inc. Press release Ceribell Expands Its Point-of-Care Brain Monitoring Platform with Commercial Launch of Delirium Monitoring Solution GlobeNewswire
CBLLCeriBell, Inc. Press release Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum GlobeNewswire
CBLLCeriBell, Inc. Press release Ceribell to Report Third Quarter 2026 Financial Results on November 3, 2026 GlobeNewswire
CBLLCeriBell, Inc. Press release Ceribell Receives FDA 510(k) Clearance for Quantitative EEG GlobeNewswire
SNOW Stock news Snowflake To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday Benzinga
CBLLCeriBell, Inc. Stock news CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push MarketBeat
CBLLCeriBell, Inc. Stock news CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript Seeking Alpha
CBLLCeriBell, Inc. Stock news Here's What Key Metrics Tell Us About CeriBell, Inc. (CBLL) Q2 Earnings Zacks Investment Research
CBLLCeriBell, Inc. Stock news CeriBell, Inc. (CBLL) Reports Q2 Loss, Tops Revenue Estimates Zacks Investment Research
CBLLCeriBell, Inc. Stock news CeriBell Q2 Earnings Call Highlights MarketBeat
CBLLCeriBell, Inc. Press release Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review GlobeNewswire
CBLLCeriBell, Inc. Press release Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System GlobeNewswire
CBLLCeriBell, Inc. Press release Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference GlobeNewswire
CBLLCeriBell, Inc. Stock news CeriBell Sees ‘Early Innings' Growth as Hospital Accounts and Usage Hit Records MarketBeat
See more
FAQ

Questions about CeriBell, Inc.

What does CeriBell, Inc. do?
CeriBell, Inc. develops AI-based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company offers the Ceribell System, a novel point-of-care EEG platform designed to address unmet needs of patients in acute care settings. It also provides EEG disposable headbands and pocket-sized battery-operated recorders. CeriBell was formerly known as Brain Stethoscope, Inc., changing its name in August 2015. The company was incorporated in 2014 and is based in Sunnyvale, California.
What is CBLL's market cap?
CeriBell, Inc. (CBLL) is a listed stock with a live quote. The latest market cap on this page is $902M.
Where is CeriBell, Inc. headquartered?
CeriBell, Inc. is headquartered in Sunnyvale, CA.
How do I get CBLL news from the API?
Call GET /v1/news?tickers=CBLL. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does CBLL news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for CBLL, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the CBLL price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs